Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of California, San Diego National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00706836 |
The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. We hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.
Condition | Intervention | Phase |
---|---|---|
Anxiety Disorders |
Drug: pregabalin Drug: placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Single Blind (Subject), Crossover Assignment |
Official Title: | PharmacofMRI of Anxiolytic Medications (Pregabalin) |
Estimated Enrollment: | 15 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Pregabalin oral tablets (50 mg)
|
Drug: pregabalin
One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
|
2: Active Comparator
Pregabalin oral tablets (200 mg)
|
Drug: pregabalin
One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
|
3: Placebo Comparator |
Drug: placebo
One dose of matched oral placebo to be administered one hour prior to fMRI scan
|
Increased amygdala and insula activity have been implicated in neurobiological models of anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to decrease activation in these areas during the processing of emotional stimuli. This study aims to replicate those results but by using a different medication, pregabalin. An eventual aim of this study, in combination with future studies, is to evaluate the utility of fMRI as a tool to identify anxiolytic function in both established and novel compounds that may be used to treat anxiety.
Ages Eligible for Study: | 18 Years to 30 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lakshmi Ravindran, MD | 858-534-7352 | lravindran@ucsd.edu |
Contact: Murray B Stein, MD,MPH | mstein@ucsd.edu |
United States, California | |
University of California, San Diego | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Lakshmi Ravindran, MD 858-534-7352 lravindran@ucsd.edu | |
Principal Investigator: Murray B Stein, MD, MPH | |
Principal Investigator: Martin Paulus, MD | |
Sub-Investigator: Lakshmi Ravindran, MD |
Principal Investigator: | Murray B Stein, MD, MPH | University of California, San Diego |
Responsible Party: | University of California, San Diego ( Murray B. Stein ) |
Study ID Numbers: | UCSD IRB 060407 - B |
Study First Received: | June 26, 2008 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00706836 |
Health Authority: | United States: Institutional Review Board |
anxiety functional magnetic resonance imaging fMRI pregabalin Lyrica |
Anxiety Disorders Mental Disorders Pregabalin |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Peripheral Nervous System Agents |
Analgesics Central Nervous System Agents Anticonvulsants Pharmacologic Actions |